Immune consequences of anti-angiogenic therapyin renal cell carcinoma

Current therapies of renal cell carcinoma (RCC), a highly vascularised tumour, mostly rely on anti-angiogenic treatment options. These include tyrosine kinase inhibitors (TKIs) and anti-VEGF monoclonal antibodies. Although these strategies aim at restraining vascularisation to control tumour growth,...

Descripción completa

Detalles Bibliográficos
Autores principales: Brodaczewska, Klaudia K., Szczylik, Cezary, Kieda, Claudine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885083/
https://www.ncbi.nlm.nih.gov/pubmed/29628789
http://dx.doi.org/10.5114/wo.2018.73878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885083/
https://www.ncbi.nlm.nih.gov/pubmed/29628789
http://dx.doi.org/10.5114/wo.2018.73878

Ejemplares similares